Company: GANX
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001558370-25-007747
Chunk: 8

Company: Gain Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part II, Item 1L
Chunk 8
---
, and we may manufacture such materials in other countries in the future.

Current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with APIs. In addition, such tariffs will increase our supply chain complexity and could also potentially disrupt our existing supply chain. Trade restrictions affecting the import of materials necessary for clinical trials could result in delays to our development timelines. Increased development costs and extended development timelines could place us at a competitive disadvantage compared to companies operating in regions with more favorable trade relationships and could reduce investor confidence, negatively impacting our ability to secure additional financing on favorable terms or at all. In addition, as we advance toward commercialization in the future, tariffs and trade restrictions